Search Clinical Trials
Sponsor Condition of Interest |
---|
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
University of Arkansas
Squamous Cell Carcinoma of Head and Neck
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin.
It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year
period in terms of reducing cancer recurrence rate by comparing the recurrence rates between... expand
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 68 subjects are eligible for injection. Type: Interventional Start Date: Feb 2024 |
Perform® Humeral System - Fracture Study (PFX)
Stryker Trauma GmbH
Traumatic Arthropathy of Shoulder
Fracture Humerus
Traumatic Arthritis
Revision of Other Devices if Sufficient Bone Stock Remains
This study is an international, single arm, multicenter, prospective follow-up,
non-significant risk, Post-Market Clinical Follow-up (PMCF), which is designed to collect
safety and performance data on commercially available Perform® Fracture.
Data collected from this study... expand
This study is an international, single arm, multicenter, prospective follow-up, non-significant risk, Post-Market Clinical Follow-up (PMCF), which is designed to collect safety and performance data on commercially available Perform® Fracture. Data collected from this study will be used for purposes, including but not limited to, PMS, peer-reviewed publications, education materials, future regulatory submissions, and/or product development. Type: Observational Start Date: Aug 2023 |
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic...
Bayer
Prevention of Ischemic Stroke
Acute Non-cardioembolic Ischemic Stroke
High-risk Transient Ischemic Attack
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a
blood clot travelled to the brain in people who within the last 72 hours had:
- an acute stroke due to a blood clot that formed outside the heart (acute
non-cardioembolic ischemic... expand
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: - an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke), or - TIA/mini-stroke with a high risk of turning into a stroke (high-risk transient ischemic attack), and who are planned to receive standard of care therapy. Acute ischemic strokes or TIA/mini-stroke result from a blocked or reduced blood flow to a part of the brain. They are caused by blood clots that travel to the brain and block the vessels that supply it. If these blood clots form elsewhere than in the heart, the stroke is called non-cardioembolic. People who already had a non-cardioembolic stroke are more likely to have another stroke. This is why they are treated preventively with an antiplatelet therapy, the current standard of care. Antiplatelet medicines prevent platelets, components of blood clotting, from clumping together. Anticoagulants are another type of medicine that prevents blood clots from forming by interfering with a process known as coagulation (or blood clotting). The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care without increasing the risk of bleeding. The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy. A placebo is a treatment that looks like a medicine but does not have any medicine in it. Another aim is to compare the occurrence of major bleeding events during the study between the asundexian and the placebo group. Major bleedings have a serious or even life-threatening impact on a person's health. Dependent on the treatment group, the participants will either take asundexian or placebo as tablets once a day for at least 3 months up to 31 months. Approximately every 3 months during the treatment period, either a phone call or a visit to the study site is scheduled on an alternating basis. In addition, one visit before and up to two visits after the treatment period are planned. During the study, the study team will: - Check vital signs such as blood pressure and heart rate - Examine the participants' heart health using an electrocardiogram (ECG) - Take blood samples - Ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study. Type: Interventional Start Date: Jan 2023 |
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
Hoffmann-La Roche
Endometrial Cancer
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and
pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid
endometrial cancer.
expand
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer. Type: Interventional Start Date: Jun 2023 |
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and...
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in
combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination
with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with
pomalidomide... expand
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd). Type: Interventional Start Date: Oct 2022 |
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory...
Kite, A Gilead Company
Relapsed/Refractory Follicular Lymphoma
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel,
works in participants with relapsed/refractory follicular lymphoma
expand
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma Type: Interventional Start Date: Sep 2022 |
First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer
Takeda
Unresectable Locally Advanced or Metastatic Cancer
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in
participants with unresectable, locally advanced or metastatic cancer who have experienced
treatment failure or are intolerant to standard therapies.
Participants will be treated... expand
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks. Type: Interventional Start Date: Apr 2022 |
Open-label Trial in Parkinson's Disease (PD)
Cerevel Therapeutics, LLC
Parkinson Disease
The purpose of this study is to evaluate the safety and efficacy of long-term administration
of flexible doses of tavapadon in participants with Parkinson's Disease.
expand
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease. Type: Interventional Start Date: Feb 2021 |
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Advanced Cancer
Metastatic Cancer
Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
This clinical trial is evaluating a drug called ART0380 in participants with advanced or
metastatic solid tumors. The main goals of this study are to:
- Find the recommended dose of ART0380 that can be given safely to participants alone and
in combination with gemcitabine... expand
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: - Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan - Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan - Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan Type: Interventional Start Date: Dec 2020 |
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal...
Alliance for Clinical Trials in Oncology
Stage II Colorectal Cancer AJCC v8
Stage III Colorectal Cancer AJCC v8
This phase II/III trial studies the best dose of duloxetine and how well it works in
preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with
oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount
of certain... expand
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy. Type: Interventional Start Date: Jun 2020 |
Ostomy Rural Telehealth Training Cancer Survivors
University of Pennsylvania
Ostomy
Quality of Life
Telehealth
Over one million individuals in the U.S. have ostomies. The American Cancer Society estimates
43,030 rectal cancer cases and 81,190 bladder cancer cases will be diagnosed in 2018.Of
these, at least 30,000 will receive ostomies, and an additional unknown number due to
gynecologic,... expand
Over one million individuals in the U.S. have ostomies. The American Cancer Society estimates 43,030 rectal cancer cases and 81,190 bladder cancer cases will be diagnosed in 2018.Of these, at least 30,000 will receive ostomies, and an additional unknown number due to gynecologic, other gastrointestinal, or other gastro-urinary tumors. The health-related quality of life impact is tremendous and greater than with many other cancer treatments. An ostomy is often a prolonged or lifelong disabling problem for cancer survivors. The adaptation period is quite variable. In our R01 study, 18% of participants took at least one year to be comfortable, or never felt comfortable, in managing their ostomy care. Importantly, many patients cannot attend in-person self-management programs or patient groups for a myriad of reasons, including distance to travel, lack of access to transportation, monetary outlays, competing demands (such as work), or comorbidities making travel difficult. In addition, a national shortage of OCNs means patients with an ostomy, whether newly placed or a long-term issue, receive little help. It is imperative to study interventions for rural survivors aimed to limit family financial burdens, improve ostomy outcomes, and improve survivors' well-being. Type: Interventional Start Date: Aug 2019 |
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer...
Alliance for Clinical Trials in Oncology
Infiltrating Bladder Urothelial Carcinoma
Stage II Bladder Urothelial Carcinoma
Stage III Bladder Urothelial Carcinoma
This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating
participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as
gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor... expand
This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Type: Interventional Start Date: Aug 2018 |
A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive...
University of Arkansas
Castration Sensitive Prostate Cancer
The goal of this clinical trial is to assess the feasibility of adding a combination of
metformin and turmeric as part of a nutritional intervention regimen to the current standard
of care, namely, intermittent Androgen Deprivation Therapy (iADT), for patients with
castration... expand
The goal of this clinical trial is to assess the feasibility of adding a combination of metformin and turmeric as part of a nutritional intervention regimen to the current standard of care, namely, intermittent Androgen Deprivation Therapy (iADT), for patients with castration sensitive biochemical progressive prostate cancer. The main objectives are: - Assess the feasibility of the study population and enrollment. - Evaluate time to PSA relapse with nutritional intervention on iADT. Participants who are receiving iADT will be dispensed Metformin and turmeric and complete a pill diary. Participants will also have blood and stool samples collected and complete quality of life questionnaires. The long-term goal is to further assess the efficacy and safety of this nutritional regimen and the roles of metabolic syndrome, microenvironment/microbiome, and genomic vs epigenomic profiles in the care of these patients through a clinical trial. Type: Interventional Start Date: Apr 2024 |
Visualization of the STN and GPi for DBS
Surgical Information Sciences Inc.
Deep Brain Stimulation
Parkinson Disease
The purpose of the study is to determine if using SIS System for DBS planning results in less
distance between the planned target location and the actual implanted lead location than DBS
planning without SIS System.
expand
The purpose of the study is to determine if using SIS System for DBS planning results in less distance between the planned target location and the actual implanted lead location than DBS planning without SIS System. Type: Observational Start Date: Oct 2023 |
In Vivo Detection of Circulating Clots in Patients With Thromboembolism
University of Arkansas
Thromboembolism
Subjects with thromboembolic disease or at high-risk for thromboembolic conditions diagnosed
with ultrasound or other standard of care techniques will be recruited to estimate the
feasibility of a device to detect in vivo CBCs.
expand
Subjects with thromboembolic disease or at high-risk for thromboembolic conditions diagnosed with ultrasound or other standard of care techniques will be recruited to estimate the feasibility of a device to detect in vivo CBCs. Type: Interventional Start Date: Jul 2023 |
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383...
TeneoOne Inc.
Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma
cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of
ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd),
lenalidomide-dexamethasone... expand
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), daratumumab-dexamethasone (Dd), or nirogacestat (Niro) in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. ABBV-383 is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. ABBV-383 co-administered with Pd, Rd, Dd, or Niro will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of ABBV-383, followed by a dose expansion phase to confirm the dose. Approximately 270 adult participants with R/R MM will be enrolled in the study in approximately 45 sites worldwide. Participants will receive intravenous (IV) ABBV-383 co-administered with oral/IV Pd, oral/IV Rd, oral/IV/subcutaneous (SC) Dd, or oral/IV Niro in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects. Type: Interventional Start Date: Oct 2022 |
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic...
Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25
mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week
treatment period.
expand
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period. Type: Interventional Start Date: Dec 2020 |
Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation...
NRG Oncology
Advanced Head and Neck Squamous Cell Carcinoma
Advanced Hypopharyngeal Squamous Cell Carcinoma
Advanced Laryngeal Squamous Cell Carcinoma
Advanced Oropharyngeal Squamous Cell Carcinoma
Squamous Cell Carcinoma of Unknown Primary
This phase II/III trial compares the effect of the combination of high-dose cisplatin every
three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for
the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy... expand
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer. Type: Interventional Start Date: Oct 2021 |
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage...
NRG Oncology
Buccal Mucosa Squamous Cell Carcinoma
Floor of Mouth Squamous Cell Carcinoma
Gingival Squamous Cell Carcinoma
Hard Palate Squamous Cell Carcinoma
Lip Squamous Cell Carcinoma
This phase II/III trial studies how well sentinel lymph node biopsy works and compares
sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for
early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that
removes... expand
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection. Type: Interventional Start Date: Jul 2020 |
Zoster Eye Disease Study
NYU Langone Health
Herpes Zoster Ophthalmicus
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of
suppressive valacyclovir for one year in immunocompetent study participants with an episode
of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis
due... expand
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment. Type: Interventional Start Date: Aug 2017 |
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
University of Pennsylvania
Castleman Disease
Castleman's Disease, Multicentric
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric
Castleman disease.
expand
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease. Type: Interventional Start Date: Sep 2019 |
Transformative Research in Diabetic Nephropathy
University of Pennsylvania
Diabetic Nephropathies
Diabetic Glomerulosclerosis
This is a prospective, observational, cohort study of patients with a clinical diagnosis of
diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect,
process, and study kidney tissue and to harvest blood, urine and genetic materials to
elucidate... expand
This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of observation. High through-put genomic analysis associated with genetic and biomarker testing will serve to identify key potential therapeutic targets for DKD by comparing patients with rapid and slow progression patterns. Each participating clinical site will search for, consent, harvest the biopsy sample, and enroll the participants as required for the TRIDENT protocol. Type: Observational Start Date: Dec 2016 |
HEALEY ALS Platform Trial - Regimen D Pridopidine
Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial
evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in
participants... expand
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS. Type: Interventional Start Date: Dec 2020 |
Statins In Intracerbral Hemorrhage
Beth Israel Deaconess Medical Center
Intracerebral Hemorrhage
The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs
after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the
decision to continue/discontinue statins should be influenced by an individual's
Apolipoprotein-E... expand
The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype. An MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cerebral small vessel disease, and whether the presence/burden of hemorrhagic markers (i.e. cerebral microbleeds and/or cortical superficial siderosis) on baseline MRI influences the risk of ICH recurrence on/off statin therapy. Type: Interventional Start Date: Jun 2020 |
Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia
Christoph Hornik
Bronchopulmonary Dysplasia of Newborn
This is a multicenter, randomized, placebo-controlled, sequential dose-escalating,
double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal
Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD).
expand
This is a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD). Type: Interventional Start Date: May 2021 |
- Previous
- Next